Table 1. Demographics and Clinical Characteristics
Overall (N=387)
Sex (Male) 261 (67.4%)
Age at procedure
Median (Q1, Q3) 68.0 (60.0, 74.0)
Range 27.0 - 87.0
Hypertension 280 (72.4%)
Diabetes Mellitus (Type II) 47 (12.1%)
Coronary artery disease 74 (19.1%)
Congestive heart failure 152 (39.3%)
Dyslipidemia 244 (63.0%)
Thyroid status
Amiodarone Induced Hyper 1 (0.3%)
Hyper 2 (0.5%)
Hypo 63 (16.3%)
None 317 (81.9%)
Subclinical Hypo 4 (1.0%)
Obstructive sleep apnea 185 (47.8%)
Chronic obstructive pulmonary disease 40 (10.3%)
Chronic kidney disease 78 (20.2%)
Pre-procedure creatinine
Median (Q1, Q3) 1.1 (0.9, 1.2)
Range 0.6 - 4.9
Atrial fibrillation/flutter status
History of atrial fibrillation/flutter without intervention 89 (23.0%)
No history of atrial fibrillation/flutter 42 (10.9%)
Previous ablation for atrial fibrillation/flutter 256 (66.1%)
Congenital heart disease 25 (6.5%)
Valve repair/replacement 59 (15.2%)
MAZE 30 (7.8%)
VT11Ventricular tachycardia/PVC22Premature ventricular contraction ablation 6 (1.6%)
AVNRT33Atrioventricular nodal reentrant tachycardia ablation 5 (1.3%)
HOCM44Hypertrophic obstructive cardiomyopathy s/p myectomy 12 (3.1%)
WPW55Wolff-Parkinson-White ablation 1 (0.3%)
Other cardiac symptoms 1 (0.3%)
Ablation success 323 (83.5%)
Acute termination 324 (83.7%)
Lack of inducibility 385 (99.5%)
Use of DCCV66Direct current cardioversion during procedure
None 322 (83.2%)
Hemodynamic Instability 2 (0.5%)
Failure of termination 63 (16.3%)